Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Dostarlimab in Advanced/Recurrent Endometrial Cancer
NCT06385548Phase 2Withdrawn
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of lurbinectedin in endometrial cancer (EC), sponsored by Vall d'Hebron Institute of Oncology. Planned start May 2024; status: withdrawn.
02
Drugs
lurbinectedin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06385548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385548.